MENU
HELX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Sep 28, 2026

HELX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for HELX turned positive on September 18, 2026. Looking at past instances where HELX's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on HELX as a result. In 69 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

Following a +0.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in 213 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 188 of 232 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

HELX broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), IQVIA Holdings (NYSE:IQV), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF (HELX) ETF is 38.93B. The market cap for tickers in the group ranges from 566.52M to 1.05T. LLY holds the highest valuation in this group at 1.05T. The lowest valued company is NGNE at 566.52M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF (HELX) ETF was 23%. For the same ETF, the average monthly price growth was 66%, and the average quarterly price growth was 307%. GRAL experienced the highest price growth at 23%, while NGNE experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF (HELX) ETF was -6%. For the same stocks of the ETF, the average monthly volume growth was 23% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 61
Price Growth Rating: 45
SMR Rating: 77
Profit Risk Rating: 75
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com